On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was shown that the vaccine was well-tolerated and generated a strong immune response in older adults. A report published in The New England Journal of Medicine described the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Lisa A. Jackson, MD, MPH, a senior investigator at Kaiser Permanente Washington Health Research Institute (KPWHRI) lead the phase 1 trial and was a co-author of the report.